Biohaven
NEWS
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
JOBS
IN THE PRESS